Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT-Reference-Cited by-同舟云学术

Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT

Published:2020-07-28 Issue:1 Volume:56 Page:218-224
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Nagler Arnon^ORCID,Baron Frédéric^ORCID,Labopin Myriam^ORCID,Polge Emmanuel,Esteve Jordi,Bazarbachi Ali,Brissot Eolia,Bug Gesine,Ciceri Fabio,Giebel Sebastian^ORCID,Gilleece Maria H.^ORCID,Gorin Norbert-Claude,Lanza Francesco,Peric Zinaida,Ruggeri Annalisa^ORCID,Sanz Jaime^ORCID,Savani Bipin N.^ORCID,Schmid Christoph,Shouval Roni,Spyridonidis Alexandros^ORCID,Versluis Jurjen^ORCID,Mohty Mohamad

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-020-01005-y.pdf

Reference39 articles.

1. Della Starza I, Chiaretti S, De Propris MS, Elia L, Cavalli M, De Novi LA. et al. Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Front Oncol. 2019;9:726. https://doi.org/10.3389/fonc.2019.00726.

2. Maffini E, Saraceni F, Lanza F. Treatment of adult patients with relapsed/refractory B-cell Philadelphia-negative acute lymphoblastic leukemia. Clin Hematol Int. 2019;1:85–93. https://doi.org/10.2991/chi.d.190503.002.

3. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580. https://doi.org/10.1001/jamaoncol.2017.0580.

4. Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36:1486–97. https://doi.org/10.1200/JCO.2017.76.3425.

5. Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:2709–16. https://doi.org/10.1200/JCO.2011.35.0371.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upregulation of the long noncoding RNA GJA9‐MYCBP and PVT1 is a potential diagnostic biomarker for acute lymphoblastic leukemia;Cancer Reports;2024-07

2. Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study;Cancer;2024-04-06

3. Monitoring Measurable/Minimal Residual Disease in Acute Myeloid Leukemia: Multiparametric Flow Cytometry-Based Approach;Indian Journal of Medical and Paediatric Oncology;2023-11-27

4. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT;Bone Marrow Transplantation;2023-08-28

5. Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy;International Journal of Hematology;2023-05-22